Non-Invasive Blood Test to Detect Prostate Cancer Launched

Share this content:

Beckman Coulter Diagnostics announced the launch of Prostate Health Index (phi), a non-invasive blood test for detecting prostate cancer. This new test is 3 times more specific in prostate cancer detection than PSA (prostate-specific antigen), decreasing the need for biopsy in male patients who test positive for elevated PSA levels.

Currently, the most commonly used test to screen for prostate cancer is the PSA test but results can often indicate the possibility of cancer when none is present. A multicenter clinical study showed a 31% reduction in unnecessary biopsies due to false-positives as a result of using the phi test.

RELATED: Prostate-specific Antigen Screening: Still Debated

The test evaluates 3 different PSA markers–PSA, freePSA, and p2PSA to better determine the probability of cancer in patients with elevated PSA levels. The phi test is now available through the Innovative Diagnostics Laboratory (IDL).

For more information call (800) 526-3821 or visit ProstateHealthIndex.us.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs